CVS Caremark to replace Humira with biosimilars on national commercial formularies

CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.
However, patients with Choice and Standard Opt Out commercial formulary coverage will still have the option to be treated with originator Humira (adalimumab, AbbVie), the company added.
According to the release, the move will “potentially save our clients more than 50% on adalimumab in 2024 than in 2022,” prior to the availability of any adalimumab

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.